{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T06:54:03Z","timestamp":1789714443181,"version":"4.0.1"},"reference-count":25,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2006,6,1]],"date-time":"2006-06-01T00:00:00Z","timestamp":1149120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,6,1]],"date-time":"2006-06-01T00:00:00Z","timestamp":1149120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","metabolismjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2006,6]]},"DOI":"10.1016\/j.metabol.2006.01.006","type":"journal-article","created":{"date-parts":[[2006,5,19]],"date-time":"2006-05-19T07:19:02Z","timestamp":1148023142000},"page":"711-721","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"title":["N-Glucuronidation of the antiepileptic drug retigabine: results from studies with human volunteers, heterologously expressed human UGTs, human liver, kidney, and liver microsomal membranes of Crigler-Najjar type II"],"prefix":"10.1016","volume":"55","author":[{"given":"J\u00fcrgen","family":"Borlak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antje","family":"Gasparic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Locher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert","family":"Schupke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Hermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.metabol.2006.01.006_bib1","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/0920-1211(95)00101-8","article-title":"D-23129: a new anticonvulsant with a broad spectrum activity in animal models of epileptic seizures","volume":"23","author":"Rostock","year":"1996","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.metabol.2006.01.006_bib2","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/0014-2999(96)00073-8","article-title":"D-23129: a potent anticonvulsant in the amygdala kindling model of complex partial seizures","volume":"303","author":"Tober","year":"1996","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.metabol.2006.01.006_bib3","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/0304-3940(95)11783-S","article-title":"Anticonvulsant properties of D-20443 genetically epilepsy-prone rats: prediction of clinical response","volume":"195","author":"Dailey","year":"1995","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.metabol.2006.01.006_bib4","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/j.1527-3458.1996.tb00304.x","article-title":"D-23129: a new anticonvulsant compound","volume":"2","author":"Kapetanovic","year":"1996","journal-title":"CNS Drug Rev"},{"key":"10.1016\/j.metabol.2006.01.006_bib5","first-page":"1063","article-title":"Investigation into the mechanism of action of the new anticonvulsant retigabine: interaction with GABAergic and glutamatergic neuro-transmission and with voltage gated Na+ and Ca++ channels","volume":"50","author":"Rundfeldt","year":"2000","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.metabol.2006.01.006_bib6","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1126\/science.282.5395.1890","article-title":"KCNQ2 and KCNQ3 potassium channel subunits: molecular correlates of the M-channel","volume":"282","author":"Wang","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.metabol.2006.01.006_bib7","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1007\/s007020050206","article-title":"Flupirtine shows functional NMDA receptor antagonism by enhancing Mg2+ block via activation of voltage independent potassium channels","volume":"106","author":"Kornhuber","year":"1999","journal-title":"J Neural Transm"},{"key":"10.1016\/j.metabol.2006.01.006_bib8","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0304-3940(00)00866-1","article-title":"The novel anticonvulsant retigabine activates M-currents in Chinese hamster ovary-cells transfected with human KCNQ2\/3 subunits","volume":"281","author":"Rundfeldt","year":"2000","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.metabol.2006.01.006_bib9","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0090-9556(24)15258-0","article-title":"Metabolism of retigabine (D-23129), a novel anticonvulsant","volume":"27","author":"Hempel","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.metabol.2006.01.006_bib10","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1002\/(SICI)1096-9888(199612)31:12<1371::AID-JMS433>3.0.CO;2-4","article-title":"Identification of talinolol metabolites in urine of man, dog, rat and mouse after oral administration by high-performance liquid chromatography\u2013thermospray tandem mass spectrometry","volume":"12","author":"Schupke","year":"1996","journal-title":"J Mass Spectrom"},{"key":"10.1016\/j.metabol.2006.01.006_bib11","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/0304-4165(90)90030-Z","article-title":"Effects of molecular substitution patterns on the cytochrome P-450 dependent metabolism of 2, 2\u2032, 3, 5, 5\u2032, 6- and 2, 2\u2032, 3, 4, 4\u2032, 6-hexachlorobiphenyl by rat live monooxygenases","volume":"1036","author":"Borlak","year":"1990","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.metabol.2006.01.006_bib12","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/0014-5793(92)81266-O","article-title":"Characterisation of a human bilirubin UDP-glucuronosyltransferase stably expressed in hamster lung fibroblast cell cultures","volume":"308","author":"Sutherland","year":"1992","journal-title":"FEBS Lett"},{"key":"10.1016\/j.metabol.2006.01.006_bib13","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0026-895X(25)10908-5","article-title":"Stable expression of two human UDP-glucuronosyltransferase cDNAs in V79 cell cultures","volume":"39","author":"Fournel-Gigleux","year":"1991","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.metabol.2006.01.006_bib14","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1042\/bj2780465","article-title":"Cloning and stable expression of a new member of the human liver phenol\/bilirubin: UDP-glucuronosyltransferase cDNA family","volume":"278","author":"Wooster","year":"1991","journal-title":"Biochem J"},{"key":"10.1016\/j.metabol.2006.01.006_bib15","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1006\/abio.1997.2443","article-title":"A universal radiochemical high-performance liquid chromatographic assay for the determination of UDP-glucuronosyltransferase activity","volume":"255","author":"Ethell","year":"1998","journal-title":"Anal Biochem"},{"key":"10.1016\/j.metabol.2006.01.006_bib16","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S0090-9556(24)15257-9","article-title":"Retigabine N-glucuronidation and its potential role in enterohepatic circulation","volume":"27","author":"Hiller","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.metabol.2006.01.006_bib17","series-title":"Goodman and Gilman's the pharmacological basis of therapeutics","first-page":"1707","article-title":"Design and optimization of dosage regimes; pharmacokinetic data","author":"Benet","year":"1996"},{"key":"10.1016\/j.metabol.2006.01.006_bib18","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1067\/mcp.2003.12","article-title":"Effects of age and sex on the disposition of retigabine","volume":"73","author":"Hermann","year":"2003","journal-title":"Clin Pharmacol Ther"},{"issue":"Suppl 3","key":"10.1016\/j.metabol.2006.01.006_bib19","first-page":"A335","article-title":"Retigabine does not alter the pharmacokinetics of a low-dose oral contraceptive in women","volume":"56","author":"Ferron","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.metabol.2006.01.006_bib20","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1046\/j.1365-2125.2003.01825.x","article-title":"Lack of pharmacokinetic interaction between retigabine and phenobarbitone at steady-state in healthy subjects","volume":"56","author":"Ferron","year":"2003","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.metabol.2006.01.006_bib21","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s00228-003-0558-6","article-title":"Pharmacokinetic interaction between retigabine and lamotrigine in healthy subjects","volume":"58","author":"Hermann","year":"2003","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.metabol.2006.01.006_bib22","series-title":"Progress report on new antiepileptic drug: a summary of the Sixth Eilat Conference (EILAT VI)","first-page":"36","article-title":"Retigabine","volume":"vol. 51","author":"Hermann","year":"2002"},{"key":"10.1016\/j.metabol.2006.01.006_bib23","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1080\/004982597240424","article-title":"In vitro glucuronidation of D-23129, a new anticonvulsant, by human liver microsomes and liver slices","volume":"27","author":"McNeilly","year":"1997","journal-title":"Xenobiotica"},{"key":"10.1016\/j.metabol.2006.01.006_bib24","first-page":"830","article-title":"N+-Glucuronidation, a common pathway in human metabolism of drugs with a tertiary amine group","volume":"26","author":"Hawes","year":"1998","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.metabol.2006.01.006_bib25","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2165\/00003088-199631010-00003","article-title":"The clinical pharmacokinetics of the newer antiepileptic drugs. Focus on topiramate, zonisamide and tiagabine","volume":"31","author":"Perucca","year":"1996","journal-title":"Clin Pharmacokinet"}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049506000370?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049506000370?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T03:08:49Z","timestamp":1758424129000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026049506000370"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,6]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2006,6]]}},"alternative-id":["S0026049506000370"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2006.01.006","relation":{},"ISSN":["0026-0495"],"issn-type":[{"value":"0026-0495","type":"print"}],"subject":[],"published":{"date-parts":[[2006,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"N-Glucuronidation of the antiepileptic drug retigabine: results from studies with human volunteers, heterologously expressed human UGTs, human liver, kidney, and liver microsomal membranes of Crigler-Najjar type II","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2006.01.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2006 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}